APLT Stock Risk & Deep Value Analysis
Applied Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About APLT Stock
We analyzed Applied Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran APLT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is APLT Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for APLT?
- âš
Further dilutive financing at unfavorable terms
- âš
Negative clinical trial results for pipeline candidates
- âš
FDA rejection of AT-007 resubmission
- âš
Potential delisting from NASDAQ due to low share price or market cap
- âš
Bankruptcy filing
Unlock APLT Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Applied Therapeutics Inc (APLT) Do?
Market Cap
$34.34M
Sector
Healthcare
Industry
Biotechnology
Employees
28
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Visit Applied Therapeutics Inc WebsiteIs APLT Stock Undervalued?
Unlock the full AI analysis for APLT
Get the complete DVR score, risk analysis, and more
Does APLT Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
APLT's 'moat,' primarily its intellectual property, is highly fragile and currently non-durable due to significant regulatory hurdles, financial instability, and lack of commercial success. Without regulatory approval and a clear path to market, the IP provides very little defensible advantage.
Moat Erosion Risks
- •Clinical trial failure or regulatory rejection of AT-007
- •Inability to secure sufficient non-dilutive funding
- •Competitors developing superior or faster-to-market treatments
- •Loss of key personnel or scientific talent
APLT Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive APLT Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated mid-March 2026)
- •Potential dilutive financing announcement
Medium-Term (6-18 months)
- •AT-007 resubmission for SORD deficiency to FDA (Likely mid-2026)
- •FDA action on AT-007 resubmission (late 2026 / early 2027)
- •Initial data from earlier-stage pipeline assets
Long-Term (18+ months)
- •AT-007 FDA approval and commercial launch
- •Significant pipeline advancement in other indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for APLT?
- ✓
Positive FDA decision on AT-007 resubmission and approval
- ✓
Announcement of significant non-dilutive financing or strategic partnership
- ✓
Substantial improvement in cash runway and burn rate
- ✓
Positive clinical data from other pipeline programs
Bull Case Analysis
See what could go right with Premium
Compare APLT to Similar Stocks
See how Applied Therapeutics Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for APLT (Applied Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
